In this study, TP‐16 was identified as a novel, potent, and selective EP4 antagonist with an excellent safety profile and pharmacokinetic properties that promoted T‐cell‐dependent tumor elimination by reprogramming IMCs. This evidence concerns the gene PTGER4 and neoplasm.